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EDITORIAL COMMENT
Coronary Flow Studies
for Risk Stratification
in Multivessel Disease
A Physiologic Bridge Too Far?*
D. Douglas Miller, MD, CM, FACC
St. Louis, Missouri
In this era of intense historical reflection on the events of
World War II, noted authors and film makers have trans-
ported a new generation back to the heroic acts and
inglorious failures of the last struggle for Europe. Steven
Spielberg’s and Tom Hanks’ Saving Private Ryan and Band
of Brothers have graphically illustrated in cinema verite
footage the soldiers’ perspective of combat. A noteworthy
forerunner of these modern epics is the Cornelius Ryan
chronicle of the World War II battle at Arnhem in Holland,
A Bridge Too Far (1), which was made into a major motion
picture of the same name. Located in eastern Holland nearly
equidistant from the three major centers of the Intermediate
Lesions: Intracoronary Flow Assessment versus 99mTc-
MIBI SPECT (ILIAS) trial (2), Arnhem in 1944 was the
site of a rare undamaged bridge across the Rhine River—a
vital artery into the heart of Nazi Germany. At Arnhem, Allied
troops suffered twice as many casualties as they did on D-Day.
Operation Market-Garden illustrates the bitter result of over-
reaching in the pursuit of a laudable strategic goal.
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Recognizing the limits of coronary angiography for func-
tionally defining intermediate coronary stenosis severity,
numerous investigators have sought a clinically valuable
physiologic “bridge” to facilitate decision making regarding
coronary artery disease (CAD) therapy. Each subsequent
study has buttressed this “bridge” and extended our under-
standing of human coronary physiology, while also pointing
out the inherent weakness of comparing lesion-specific
physiologic end points to noninvasive imaging and angio-
graphic data, even in the same patients. How, then, does the
battle for the bridge at Arnhem inform us about the ILIAS
(2) study? Has the intense competition among renowned
coronary physiology investigators in the Netherlands
stretched this technology beyond the limits of clinical
applicability? Have the ILIAS investigators made a tactical
error in the inception and execution of their ambitious
study? Or is this trial a victorious assault on current
diagnostic and prognostic thinking that will long influence
the course of cardiology practice?
THE ILIAS MISSION
The multicenter ILIAS investigator group has prospectively
collected and analyzed flow wire and single-photon emis-
sion computed tomographic (SPECT) imaging data from
191 patients with multivessel disease and stable angina who
were scheduled for elective percutaneous transluminal cor-
onary angioplasty (PTCA) of the most severe angiographic
stenosis. The investigators followed these patients one year
for subsequent cardiac events, including myocardial infarc-
tion (MI) and death (“hard” events), and ischemia-driven
coronary revascularization. Despite previous outcomes data
from the Doppler Endpoints Balloon Angioplasty Trial
Europe (DEBATE) study (3), a coronary flow velocity
reserve (CFVR) cut point of 2.0 and the presence of a
reversible SPECT perfusion defect change 1 grade de-
fined testing abnormalities in the index artery and perfusion
bed, respectively. The majority of subsequent events (16 of
19) were coronary revascularizations, of which 13 patients
had myocardial ischemia documented prior to subsequent
coronary artery bypass graft surgery (CABG) or percutane-
ous coronary intervention (PCI).
This study enrolled sufficiently large numbers of patients
for statistical validity, and it was carried out by skilled
investigators blinded to the critical data elements. Two very
different physiologic techniques (coronary flow wire and
myocardial SPECT) were compared under nonidentical
drug stress conditions (adenosine vs. dipyridamole infu-
sion). Not surprisingly, the comparability of the two mea-
surements was low (70%) and inconsistent with that re-
ported in previous studies in largely single-vessel disease
populations, in which good agreement (90%) was
achieved between flow wire and SPECT data (4–10). This
is likely explained by the complexities associated with
multivessel coronary disease physiology, and by the fact that
a direct measurement of flow enhancement during hyper-
emia (relative to basal index vessel flow) was compared to an
imaging technique that measures flow enhancement in
diverse myocardial beds using relative radiotracer uptake
detected with SPECT. Neither technique provides an
absolute measurement of myocardial perfusion, nor coro-
nary blood flow enhancement. In addition, the assignment
and comparability of vascular territories by flow wire and
SPECT imaging is problematic, particularly in patients
with multivessel disease. It is difficult to control for the
effects of collateral vessels, competitive flow, differential
hyperemia and other factors.
THE CASUALTY REPORT
As every small skirmish or global conflict winds down to an
inevitable conclusion, all combatants have one fervent
with—“Don’t let me be the last casualty!” While the ILIAS
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trial is the first study of its size to compare these two
techniques in a population of multivessel-disease patients, it
has clearly been shown as early as 1995 that a normal flow
wire measurement can prompt the safe deferral of a coronary
intervention in stable angina patients (11). The struggle to
optimize the clinical application of this novel intracoronary
biomedical technology continues on several fronts. To
appropriately assess whether this battle is being won, the
casualty figures—major adverse cardiac events (MACE) and
hard events (death or MI)—must be separated and carefully
scrutinized.
The ILIAS study’s potentially most troubling new find-
ing is that a normal SPECT in the perfusion territory of an
intermediate stenosis is associated with a higher than
expected MACE rate in a stable angina population, despite
standard clinical interventions (i.e., risk factor modification,
drugs, other factors) designed to reduce ischemia and retard
disease progression. It is also of note that the MACE rate
observed in ILIAS patients with normal flow enhancement
was 6%, as compared to the MACE rate in patients without
significant SPECT defect redistribution (11%) (Table 1).
These two rates do not differ significantly from each other,
but both are significantly higher than the hard event rates
previously recorded with normal or near-normal myocardial
SPECT (Table 2) or stress echocardiography in similar
populations (averaging 1.0% per year).
How can this be explained? Clearly, the majority of
events observed in ILIAS were elective coronary revascular-
izations. In an attempt to reduce subjectivity from clinical
decision making in the study, the investigators used a proxy
of ischemia as the principal determinant of the decision to
perform coronary revascularization. This is consistent with
recent American College of Cardiology/American Heart As-
sociation Guidelines (12), as is the use of coronary physiologic
assessment to assess intermediate (30% to 70%) coronary
lesions before PCI (13). Seventeen patients without a reversible
SPECT defect change of 1 grade had subsequent events,
again predominately coronary revascularizations.
All ILIAS patients had multivessel disease. Ischemia
leading to coronary revascularization events could have
occurred in the distribution of a previous PTCA vessel, or
could be due to progression of CAD in other vessels.
Revascularization events (n  59 total) could have included
PTCA of a restenotic or new lesion, or CABG of other
vessels and/or the intermediate stenosis. The relationship of
the initial physiologic studies (CFVR and SPECT) to
subsequent revascularization requires further comment. Pre-
vious studies have shown that mild to moderate SPECT
defects are actually more predictive of future adverse events
(MI) than are severe defects (14) in patients with chest pain.
It is important to understand fully the relationship of the
revascularization events and other hard events to the previ-
ously identified intermediate lesions, which are prone to
plaque rupture (15).
Table 1. Normal Coronary Physiology in Stable Angina
Study (Date)
Patients
(n)
Definition of
Normal
Stress
Modality
Multivessel
CAD (%)
PTCA
Deferred
(n)
Average
Follow-Up
(Months)
MACE* in
Deferred Patients
(%)
Annual Death/MI
in Deferred
Patients (%)
Kern et al. (1995) (11) 139 CFVR 2.0 Ex. or Drug Y (74%) 88 9 14.0 2.3
Bech et al. (1998) (16) 100 FFR myo 0.75 Ex. Y (36%) 100 18 10.0 1.0
Ferrari et al. (1999) (18) 70 CFVR 2.0 Ex. Y 22 15 9.1 0
Bech et al. (2001) (17) 325 FFR myo 0.75 — Y (38%) 91 24 11.0 1.0
ILIAS (2002) (2) 191 CFVR 2.0 Drug Y (100%) 182 12 7.0 2.1
Total 825 — — — 483
(Average) (165) (97) (15.6) (10.2) (1.3)
*MACE  major adverse cardiac events (death, myocardial infarction [MI], unstable angina, percutaneous transluminal coronary angioplasty [PTCA], coronary artery bypass
graft surgery.
CAD coronary artery disease; CFVR coronary flow velocity reserve; Ex. exercise stress; FFR myomyocardial fractional flow reserve; ILIAS Intermediate Lesions:
Intracoronary Flow Assessment versus 99mTc-MIBI SPECT; Y  yes.
Table 2. Normal Myocardial Perfusion in Stable Angina
Study (Date)
Patients
(n) SPECT Definition of Normal
Stress
Modality
Multivessel
CAD
Average
Follow-Up
(Months)
Annual Death/MI
in SPECT
Normals (%)
Schaler et al. (1993) (29) 164 No defect (Tc201) Ex. Y 34 0
Fattah et al. (1994) (30) 97 No defect (Tc201) Ex. Y 32 1.2
Stratmann et al. (1994) (31) 548 No defect (Tc99m MIBI) Ex. Y 13 0.5
Heller et al. (1995) (8) 512 No defect (Tc99m MIBI) Drug (Dipy.) Y 18 1.7
Hachamovitch et al. (1996) (14) 1,623 No minor defect (Tc99m MIBI) Ex. Y 18.8 0.3
ILIAS (2002) (2) 191 No reversible defect Drug (Dipy.) Y 18 1.9*
Total 3,135 — — —
(Average) (523) (21.3) (0.9)
*MACE  major adverse cardiac events (death, myocardial infarction [MI], unstable angina, percutaneous transluminal coronary angioplasty, coronary artery bypass graft
surgery  17 of 161 patients (11%); MACE not available for other studies.
CAD coronary artery disease; Dipy. dipyridamole; Ex. exercise; ILIAS Intermediate Lesions: Intracoronary Flow Assessment versus 99mTc-MIBI SPECT; SPECT
 single-photon emission computed tomography; Y  yes.
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It is clearly difficult to predict from the ILIAS trial
whether the intermediate lesion or the more severe PTCA
lesion exerts a greater influence on future patient outcomes
beyond one year. The one-year hard event rate related to
intermediate lesions with normal coronary physiology was
relatively low (2%), suggesting that severe lesions were the
major driver of not only future revascularizations but also of
MI and death. However, hard events (death or MI) related
to more severe lesions are not detailed in the ILIAS study.
Table 1 summarizes MACE and hard event rates in five
studies (including ILIAS) using coronary physiology to
make decisions on deferral of PCI in patients with inter-
mediate lesions.
Despite these significant limitations, Kern et al. (11) and
later other investigators (16–18) showed that deferring
interventions on intermediate coronary stenoses with nor-
mal physiology was consistently associated with low near-
term MACE rates (10%) over one to two years. The
ILIAS trial extends the existing evidence in favor of an
intermediate coronary stenosis “warranty” by showing a
similar low event rate (6% combined MI and revasculariza-
tion), and no deaths over one year after PCI deferral in a
normal physiology subset of a population with exclusively
multivessel coronary disease (2). The durability of this
warranty depends significantly on the underlying biology of
the coronary artery plaque, but it generally confers a low
hard event rate of 1% to 2% annually for a term of 12
months in stable angina patients (Fig. 1).
SUPPORTING UNITS
Ever since our original 1994 report correlating coronary
flow velocity with technetium-99m sestamibi myocardial
SPECT imaging (5), at least 14 studies have been reported
describing the relationship between catheterization
laboratory-derived physiology measures of coronary stenosis
severity and ischemia testing modalities (4,6–10,19–26).
The list includes a previous study in the Journal of the
American College of Cardiology on two-vessel coronary dis-
ease patients from several of the principal authors of the
ILIAS trial (23). The ongoing Clinical Outcomes Utilizing
Revascularization and Aggressive Drug Evaluation
(COURAGE) trial may provide further insights into the
use of SPECT to guide CAD therapies (W. Boden, personal
communication, January 16, 2002). However, outside the
setting of clinical trials and despite practice guideline
recommendations (12), only 60% to 70% of stable angina
patients undergo ischemia testing before diagnostic coro-
nary angiography.
Like the unpredictable weather around the Arnhem
“drop zone,” one cannot control for the impact of microcir-
culatory flow impairment (due to prior MI, acute coronary
syndromes, severe hypertension, diabetes and/or ventricular
hypertrophy). Nor should it be assumed that “culprit vessel”
interventions based on either abnormal coronary physiology
or ischemia stress testing will correct all symptoms, post-
stenotic flow or myocardial perfusion abnormalities in patients
with diffusely atherosclerotic arteries (27). It is now recognized,
largely based on other seminal work from Dutch investigators
(4,9), that abnormalities of flow (CFVR) may reflect either
epicardial or microvascular CAD, but that the translesional
pressure-derived index, myocardial fractional flow reserve, is
not only a more reliable measure of physiologic impairment but
also a marker of outcomes after PCI deferral (16,17) (Table 1).
EPILOGUE
In the ILIAS trial, as in general cardiology practice, it is
clear that coronary revascularization decisions following
coronary intervention in patients with multivessel disease
Figure 1. Schematic graph illustrating the cardiac “hard” event-free survival (E) without myocardial infarction or death over time (T) following a normal
test (t) performed to evaluate patients with either an acute coronary syndrome (ACS) or stable coronary artery disease (CAD). The duration of the event-free
“warranty” is dependent on CAD biology, with a shorter event-free survival expected following a normal test in patients with ACS (t 1 6 to 12 months),
compared to the extended normal post-test event-free survival in patients with stable CAD (t  2  12 to 18 months). With the passage of time following
a normal test, the 95% confidence intervals (CI) are significantly increased as the durability of the post-test risk prediction declines. The normal test in
question could be an invasive coronary physiology study or a noninvasive stress myocardial perfusion scan.
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are principally driven by other severe lesions, and not by
restenosis of the index intermediate lesion. The implication
that CFVR can be used electively to sample individual
arterial beds for coronary intervention selection (or deferral)
in patients with multivessel disease and simultaneously
define future outcomes, to the exclusion of myocardial stress
imaging, is contentious. By restricting their SPECT analysis
to myocardial perfusion data only, the ILIAS investigators
failed to take advantage of the prognostic power of several
well-validated nonmyocardial functional risk markers that
can be obtained during standard myocardial perfusion to-
mography (i.e., transiently increased tracer lung uptake,
cardiac dilation, reduced ejection fraction, increased end-
systolic volume, among others).
It must also be pointed out that seemingly appropriate
catheterization laboratory decisions made in real time may
not reflect the cumulative myocardial burden of ischemia in
daily life, which may be better reflected by tomographic
stress myocardial perfusion studies. Just as the Allied ground
unit commanders at Arnhem made numerous seemingly
correct decisions based on available information in the heat
of battle, the incremental value afforded to the operation’s
planners—distant general staff officers’ ability to see the
bigger picture at critical junctures in the battle—was cut off
by poor communications.
A seasoned warrior always favors good intelligence over
random acts of heroism. So it is with defining the future risk
of cardiac events in patients with known or suspected
multivessel coronary disease. Experienced clinicians will
continue to make the majority of their patient treatment
decisions on the basis of tomographic stress imaging data
(nuclear or echocardiographic), which simultaneously sam-
ples the cumulative physiologic impact of all critical and
intermediate lesions and provides incremental prognostic
power over the exercise, angiographic (28–31) flow, pres-
sure or data obtained in the same population. Forcing the
risk-stratification decision in multivessel disease patients
into the catheterization laboratory, even in the hands of the
best-equipped and most skilled of operators such as the
ILIAS investigators, asks too much of an elegant technology
that has other significant and useful applications. Though
the mission was well conceived and well executed by leading
investigators, in retrospect their goal was unachievable from
the onset.
The inevitability of world peace, like the march of
technology, cannot be denied. This will not be the last
report on the value of intracoronary devices for the assess-
ment of lesions’ severity, as a guide to acute intervention or
future event risk. And just as the Allies eventually succeeded
in crossing the Rhine and in winning the war, so too will the
increasing impact of physiologic testing in the laboratory
eventually become accepted as a routine adjunct to coronary
angiography. However, by knowing the limits of technol-
ogy, operators using this approach will benefit the majority
of patients with multivessel disease by restricting themselves
to making important real-time coronary lesion assessments
as a guide to interventional decision making, and not using
it as an index of future cardiac risk, where other more
powerful and better validated approaches such as myocardial
perfusion imaging are available.
Better to regroup, retrench and live to fight another day
than to undertake an ill-fated campaign against insur-
mountable odds. After all, another monument to military
hubris lies only a few kilometers to the southwest of
Arnhem—in another European low-country village named
Waterloo.
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